Michael Bishop

3 days ago | targetedonc.com | Catherine Lee |Michael Bishop |Paul Shaughnessy

Treatment Approaches (Part 1) For newly diagnosed moderate to severe cGVHD, the panel discussed: Initial steroid dosing: Dr Bishop: 1 mg/kg/day for severe cases, possibly split dosing Dr Shaughnessy: 0.5 mg/kg/day for many cases, 1 mg/kg/day for severe lung or liver involvement All agree on assessing response for at least 1-2 weeks before tapering Steroid taper considerations: Slow, cautious tapers, especially for cGVHD (unlike acute GVHD) Generally 10 mg every 1-2 weeks after stabilization,...

3 days ago | targetedonc.com | Catherine Lee |Michael Bishop |Paul Shaughnessy

Clinical Case Presentation (Part 1)A 50-year-old woman underwent allogeneic transplant with reduced-intensity conditioning from a matched unrelated donor for mesenchymal stromal cells. Her donor was a cytomegalovirus-negative 45-year-old man, and GVHD prophylaxis was tacrolimus and mycophenolate mofetil.

1 week ago | targetedonc.com | Catherine Lee |Michael Bishop |Paul Shaughnessy

Difficult-to-Diagnose Manifestations The panelists discussed challenging presentations: Pulmonary involvement is often insidious, requiring careful monitoring with serial PFTs Genital/gynecologic involvement is often underdiagnosed but impacts quality of life significantly Neuropathies are difficult to attribute to cGVHD due to multiple potential causes Peripheral edema can make assessment of skin thickening/sclerosis challenging Serositis (inflammation of tissue lining around heart, lungs,...

1 week ago | targetedonc.com | Catherine Lee |Michael Bishop |Paul Shaughnessy

Diagnosis and Clinical ChallengesFor diagnosis, the panel generally relies on clinical features rather than biopsies for typical presentations.

2 weeks ago | targetedonc.com | Catherine Lee |Michael Bishop |Paul Shaughnessy

Overview and Pathophysiology of cGVHDThe panel featured Dr Catherine Lee (Fred Hutch Cancer Center), Dr Michael Bishop (University of Chicago), and Dr Paul Shaughnessy (Sarah Cannon Transplant cellular therapy program).